Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda (pembrolizumab), for global markets.

EQS-News: Formycon AG / Key word(s): Regulatory ApprovalLucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil 05.06.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Dr. Reddy’s Laboratories RDY announced that it has entered into a collaboration and license agreement with Alvotech ALVO to co-develop and commercialize a biosimilar candidate to Merck’s MRK ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach. Worldwide sales of Keytruda in 2024 were $29.5 billion June 5, 2025 e-Paper ...

FDA grants interchangeability designation for Humira biosimilar to Samsung Bioepis, Organon . Hadlima is now interchangeable with all presentations of Humira. Sandra Levy. 6/3/2025.

Dr. Reddy’s Laboratories RDY announced that it has entered into a collaboration and license agreement with Alvotech ALVO to co-develop and commercialize a biosimilar candidate to Merck’s MRK ...

Serve You Rx, a pharmacy benefit manager, has added two recently approved biosimilars to Stelara to its formulary, the company announced Thursday. Milwaukee, Wisconsin-based Serve You Rx is an ...

With more biosimilar options available, we’ve seen a significant uptick in biosimilar market share. For example, Zarxio has captured more than 50% of market share in the Filgrastim market since ...

Keytruda posted global sales of $29.5 billion in 2024, making it a major target for biosimilar development. Alvotech and Dr. Reddy's will share development, manufacturing, and commercialization ...

The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.